Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies

Neurology

Volumn 52, Issue 5, 1999, Pages 932-937

  Turjanski, Nora ^b   Lees, A J ^a   Brooks, D J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; CARBON 11; DOPA; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUORINE 18; LEVODOPA; RACLOPRIDE; ROPINIROLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; RECEPTOR BINDING; RESTLESS LEGS SYNDROME;

EID: 0033596829     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.5.932     Document Type: Article

References (38)

1. Ekbom KA. Restless legs syndrome. Neurology 1960;10:868-873.
2. Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994;17:739-743.
3. Gibb WRG, Lees AJ. The restless legs syndrome. Postgrad Med J 1986;62:329-333.
4. Walters AS, Hening WA, Chokroverty S. Review and videotape recognition of idiopathic restless legs syndrome. Mov Disord 1991;6:105-110.
5. Ekbom KA. Restless legs. Acta Med Scand 1945;158(suppl):1-123.
6. Wetter TC, Pollmacher T. Restless legs and periodic leg movements in sleep syndromes. J Neurol 1997;244(suppl 1):S37-S45.
7. Walters AS, Hickey K, Maltzman J, et al. A questionnaire study of 138 patients with restless legs syndrome: the 'nightwalkers' survey. Neurology 1996;46:92-95.
8. Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology 1996;47:1435-1441.
9. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988;38:1845-1848.
10. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982;39:739. Letter.
11. Nordstrom AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 1992; 106:433-438.
12. Staedt J, Stoppe G, Kogler A, et al. Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration. Eur Arch Psychiatry Clin Neurosci 1995;245:8-10.
13. Montplaisir J, Godbout R, Boghen D, DeChamplain J, Young SN, Lapierre G. Familial restless legs with periodic movements in sleep: electrophysiologic, biochemical and pharmacologic study. Neurology 1985;35:130-134.
14. Walters A, the International Restless Legs Syndrome Study Group. Toward a better definition of the restless legs syndrome. Mov Disord 1995;10:634-642.
15. O'Keefe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing 1994;23:200-203.
16. Spinks TJ, Jones T, Gilardi MC, Heather JD. Physical performance of the latest generation of commercial positron scanner. IEEE Trans Nucl Sci 1988;35:721-725.
17. Robb RA. A software system for interactive and quantitative analysis of biomedical images. In: Hohne KH, Fuchs H, Pizer SM, eds. 3D Imaging in medicine. NATO ASI Series 1990: 333-361.
18. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system, in patients with multiple system atrophy, pure autonomie failure, and Parkinson's disease, studied with PET. Brain 1990;113:1539-1552.
19. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
20. Hume SP, Myers R, Bloomfield PM, et al. Quantitation of carbon-11 labelled raclopride in rat striatum using positron emission tomography. Synapse 1992;12:47-54.
21. 2 receptor binding in the living human brain by PET. Science 1986;231:258-261.
22. 11C]raclopride studies. J Cereb Blood Flow Metab 1996;16:42-52.
23. Lammerstma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4:153-158.
24. Marconi R, Lefebvre-Caparros D, Bonnet A-M, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease. Phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
25. Tarsy D. Akathisia. In: Joseph AB, Young RR, eds. Movement disorders in neurology and neuropsychiatry. Boston: Blackwell Scientific Publications, 1992:88-99.
26. Hening WA, Walters AS, Campbell S, et al. RLS symptoms peak on the falling phase of the core temperature circadian cycle. Neurology 1998;50(suppl):A68. Abstract.
27. Sowers JR, Vlachakis N. Circadian variations in plasma dopamine levels in man. J Endocrinol Invest 1984;7:341-345.
28. Trenkwalder C, Walters AS, Hening W, et al. Positron emission tomographic studies in the restless legs syndrome. Mov Disord 1999 (in press).
29. Brooks DJ. Functional imaging of movement disorders. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. 3rd ed. New York: William & Wilkins, 1998:991-1016.
30. 2 site binding in L-dopa treated Parkinson's disease patients with and without dyskinesias. Neurology 1997;49:717-723.
31. 2 receptor binding in patients with Huntington's disease and other choreas: a PET study. Brain 1995;118: 689-696.
32. Bucher SF, Trenkwalder C, Oertel WH. Reflex studies and MRI in the restless legs syndrome. Acta Neurol Scand 1996; 94:145-150.
33. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997;94:2569-2574.
34. Bannon MJ, Roth RH. Pharmacology of mesocortical dopamine neurons. Pharmacol Rev 1983;35:53-68.
35. Wilkinson LS. The nature of interactions involving prefrontal and striatal dopamine systems. J Psychopharmacol 1997;11:143-150.
36. Bucher SF, Seelos KC, Oertel WH, Reiser M, Trenkwalder C. Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann Neurol 1997;41:639-645.
37. 2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome. J Neural Transm Gen Sect 1995; 99:187-193.
38. 2 receptor binding in the rat frontal cortex. Pharmacol Biochem Behav 1995;52:43-48.